Form 4: MapLight Therapeutics GC Executes Planned Stock Sale

General Counsel Kristopher Hanson sold 13,917 shares of MapLight Therapeutics common stock via a pre-arranged 10b5-1 trading plan.

Summary

• General Counsel Kristopher Hanson sold a total of 13,917 shares of Voting Common Stock on May 11, 2026.
• The sales were executed in four tranches at weighted average prices ranging from $27.61 to $30.56 per share.
• Following these transactions, the reporting person retains beneficial ownership of 162,331 shares.
• All transactions were conducted under a Rule 10b5-1 trading plan adopted on December 29, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and executed through a standard 10b5-1 mechanism, indicating routine financial planning rather than a reaction to company performance.

Positives

• The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading by scheduling sales in advance.

Negatives

• The transaction represents a reduction in the equity stake held by a key member of the executive leadership team.

Risks

• Continued selling by insiders may be perceived negatively by the market, potentially impacting short-term share price sentiment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard corporate governance practice for executives to diversify their holdings while maintaining compliance with securities laws, and it generally does not signal a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The use of a 10b5-1 plan is the industry standard for executive stock liquidation to mitigate regulatory scrutiny.
• The volume of shares sold is relatively minor compared to the total outstanding shares, which is typical for executive portfolio rebalancing.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was conducted via a pre-arranged plan.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Insider Trading, Form 4, General Counsel, Equity Sale